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OBJECTIVE: Ovarian mucinous metastases commonly present as the first sign of the disease and are capable of
simulating primary tumors. Our aim was to investigate the role of intratumoral lymphatic vascular density
together with other surgical-pathological features in distinguishing primary from secondary mucinous ovarian
tumors.
METHODS: A total of 124 cases of mucinous tumors in the ovary (63 primary and 61 metastatic) were compared
according to their clinicopathological features and immunohistochemical profiles. The intratumoral lymphatic
vascular density was quantified by counting the number of vessels stained by the D2-40 antibody.
RESULTS:Metastases occurred in older patients and were associated with a higher proportion of tumors smaller
than 10.0 cm; bilaterality; extensive necrosis; extraovarian extension; increased expression of cytokeratin 20,
CDX2, CA19.9 and MUC2; and decreased expression of cytokeratin 7, CA125 and MUC5AC. The lymphatic
vascular density was increased among primary tumors. However, after multivariate analysis, the best predictors
of a secondary tumor were a size of 10.0 cm or less, bilaterality and cytokeratin 7 negativity. Lack of MUC2
expression was an important factor excluding metastasis.
CONCLUSIONS: The higher intratumoral lymphatic vascular density in primary tumors when compared with
secondary lesions suggests differences in the microenvironment. However, considering the differential
diagnosis, the best discriminator of a secondary tumor is the combination of tumor size, laterality and the
pattern of expression of cytokeratin 7 and MUC2.
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& INTRODUCTION
Malignant epithelial tumors account for 90% of all ovarian
cancers and are the most lethal gynecological neoplasia (1).
Primary mucinous tumors are not as frequent as serous
tumors and account for 10-15% of all ovarian neoplasms.
Approximately 80% are benign (adenomas), 10-12% are
borderline and only 3-4% correspond to primary ovarian
carcinomas (1). This last value was estimated after the
recognition and exclusion of metastatic carcinomas simulat-
ing primary tumors in the ovaries (2,3). Secondary muci-
nous carcinomas in the ovaries can mimic primary ovarian
carcinomas and even borderline tumors (4). The most
common sources of secondary tumors are the colorectum,
breast, stomach, endometrium, appendix, endocervix, pan-
creas and bile ducts (5). Primary mucinous ovarian
carcinomas are therefore rare, generally unilateral and
larger than 13 cm (4,6). Despite the refined diagnostic
criteria and current ancillary techniques, particularly the
coordinated expression of cytokeratins 7 and 20 (7), the
problem of distinguishing primary from metastatic carcino-
mas persists in at least 15% of mucinous ovarian tumors.
Epithelial ovarian tumors present a variable stromal
component that is particularly remarkable among those of
the mucinous subtype. The most striking example is the
Krukenberg tumor, which exhibits a unique cellular stroma.
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During cancer development, the stroma is remodeled to
support cancer cell proliferation, migration, invasion, or
metastasis. Lymphatic vessels are an important component
of intratumoral stroma and are also responsible for creating
conduits for tumor metastasis.
To the best of our knowledge, no studies have compared
the intratumoral lymphatic vascular density (LVD) between
primary and secondary mucinous ovarian tumors as a
means of distinguishing between these tumors. Therefore,
we proposed to investigate a potential role for LVD in the
differential diagnosis of borderline and malignant mucinous
ovarian tumors via the quantification of lymphatic vessels
identified by podoplanin expression.
& MATERIALS AND METHODS
Selection of cases
Cases of mucinous tumors in the ovary were identified
from the surgical pathology files of the Division of
Pathology of Hospital das Clı´nicas da Faculdade de
Medicina da Universidade de Sa˜o Paulo (Sa˜o Paulo/SP)
and from Consultoria em Patologia (Botucatu/SP), which is
a private reference pathology laboratory. We included cases
with borderline and malignant mucinous histologies for
which the following were available: information about the
primary site, paraffin blocks and at least one representative
histologic section taken from each centimeter of the tumor.
A total of 124 cases from 1996 to 2005 (Universidade de
Sa˜o Paulo) and from 2004 to 2011 (Consultoria em Patologia)
met the inclusion criteria. The distribution of these cases
according to their diagnosis and the primary site is shown
in Table 1. The age of this cohort ranged from 16 to 81
years (50.2¡15.8 years). From both the pathology report
and the surgery description, we obtained information
about laterality, tumor size and extraovarian extension,
including the presence of pseudomyxoma. Slides from
all cases were reviewed by two pathologists (BGLA and
CRF). Doubtful cases were analyzed under a dual-head
microscope by a third pathologist (FMC). The tumors
were classified according to the presence and type of
stromal invasion (infiltrative/destructive, multinodular and
expansive/confluent) (Figure 1), cellular type (Mullerian,
intestinal, pyloric, gastrointestinal, mixed Mullerian/intest-
inal and indeterminate) (Figure 2), histologic grade accord-
ing to the Silverberg System (8), necrosis extension (focal,
less than 50% or more than 50%) and peritumoral vascular
involvement.
The caseswere grouped as primary (Group 1) and secondary
(Group 2) tumors. Primary tumors were borderline tumors
without associated pseudomyxoma and adenocarcinomas
without clinical or surgical suspicions of other neoplasia.
Among the secondary tumors, we included borderline
tumors associated with pseudomyxoma peritonei and
adenocarcinomas with a known primary mucinous carci-
noma at another site with a morphology similar to that of the
ovarian tumor. Sixty-three tumors were classified as primary
ovarian tumors and 61 tumors were classified as secondary
ovarian tumors. We selected a representative area of the
tumor for tissue microarray (TMA) construction and immu-
nohistochemical study.
Tissue microarray construction
TMA construction was conducted at the Consultoria em
Patologia (Botucatu, SP). Representative areas were identi-
fied on slides stained with hematoxylin and eosin and
marked on paraffin blocks. Cylindrical tissues with a
diameter of 2.0 mm were punched from the areas of interest
of the donor paraffin block and mounted into the recipient
block with 1.0-mm intervals between the cores using a
precision microarray instrument (Beecher Instruments,
Silver Spring, MD) positioned on a fixed sideboard. The
cores were organized in lines and columns using the hepatic
tissue for orientation in Position 1A. After a final config-
uration of the recipient blocks, they were heated at 60 C˚ for
10 minutes and sealed with the Paraffin Tape-Transfer
System (Instrumedics, St. Louis, MO) for sectioning using
the appropriate slides (StarfrostH slides) and a microtome at
3-mm intervals (Leica Instruments, Wetzlar, Germany). The
first histological sections were stained with hematoxylin-
eosin to identify losses for eventual study in whole sections.
Immunohistochemical analysis
Immunohistochemical detection of cytokeratin 7 (CK7),
cytokeratin 20 (CK20), CA125, CDX-2, CA19.9, MUC2,
MUC5AC and podoplanin was performed using slides
from TMA blocks. The sources and dilutions of the
antibodies as well as the epitope retrieval methods used
are listed in Table 2. Bound antibodies were detected using
NovolinkH (Leica, Bannockburn, IL, USA). For all the
markers, with the exception of podoplanin, any percentage
of unequivocally positive neoplastic cells was scored as
positive for the markers, although all the positive cases
showed more than 10% stained cells. Identification of
lymphatic vessels was established based on the presence
of cells that were positive for podoplanin and that had a
morphology consistent with vessel structure (Figure 3). In
tumor sections that were negative for podoplanin staining,
adjacent lymphatic endothelial cells that appeared normal
served as positive internal controls.
Table 1 - Distribution of the mucinous ovarian tumors included in this study.
Diagnosis Type/Primary Site N (%)
Primary ovarian tumors Borderline without pseudomyxoma peritonei 30 (24.19%)
Adenocarcinoma 33 (26.61%)
Secondary ovarian tumors Borderline associated with pseudomyxoma peritonei 8 (6.45%)





unknown (disseminated disease) 2 (1.61%)
Total 124
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Quantification of lymphatic vascular density
The quantification of LVD was performed as previously
described by our group (9-11). Briefly, stained TMA
histologic sections were analyzed using standard light
microscopy (Nikon, Eclipse 200). Under low magnification,
the most vascularized intratumoral areas were identified.
We counted the number of immunostained lymphatic
vessels found in 10 ‘‘hot spot’’ areas at 400X magnification.
The LVD for each case was expressed by the mean value
(total number of vessels in 10 hot spot microscopic fields/
10). The median of all the mean LVD values was the cutoff
used to divide tumors into high or low LVD, as suggested
by Hall et al. (12).
Statistical analysis
A t-test was used to compare the ages of patients in
Group 1 (primary tumors) and Group 2 (secondary tumors)
after confirmation of a normal distribution by the
Kolmogorov-Smirnov test. The Chi-square test was used
to evaluate the association of the categorical variables within
the two groups. The odds ratio with a 95% confidence
interval was calculated for these variables. LVD was
analyzed either as a dichotomous variable or as a
continuous variable. The median (0.8) value was the cut-
off used to determine low or high LVD. Continuous LVD
values were compared between primary and secondary
tumors using the Mann-Whitney U test. The correlation
between continuous LVD and tumor size was tested using
Spearman’s rank correlation. For multivariate analysis, the
selected variables were analyzed with logistic regression
using the stepwise method. Statistical analyses were
performed using MedCalc for Windows (version 11.5.0.0;
MedCalc Software, Mariakerke, Belgium), and p-values less
than 0.05 were considered significant.
Ethics statement
This study was approved by the Scientific Committee of
the Department of Pathology of the Faculdade de Medicina
da Universidade de Sa˜o Paulo and by the Ethics Committee
for Research Projects of the Hospital das Clı´nicas da
Faculdade de Medicina da Universidade de Sa˜o Paulo
(Comissa˜o de E´tica para Ana´lise de Pesquisa - CAPPesq)
(process number 1312/09).
& RESULTS
Patients with primary tumors were younger than those
with secondary tumors, with mean values of 46.3 years and
54.0 years, respectively (p= 0.007). Sixty-seven (54.03%) of
the cases exhibited an intestinal phenotype and only 7
(5.6%) presented pure Mullerian differentiation. Other
tumors presented the following morphological phenotypes:
10 (8.06%) pyloric, 19 (15.32%) pyloric and intestinal, 7
(5.64%) mixed Mullerian and intestinal and 14 (11.29%)
indeterminate. All tumors with diffuse or partial Mullerian
differentiation were primary. Among the 93 cases with a
diffuse or partial intestinal pattern, 42 (45.1%) were primary
and 51 (54.8%) were secondary. Peritumoral vascular
invasion was observed in only three cases, all of which
were secondary tumors. The LVD values ranged from 0 to
10.1 (1.6¡2.0). There was no correlation between tumor size
and LVD (rho= 0.88; p= 0.89) or between age and LVD
(rho = 0.04). The LVD was lower in secondary tumors
(median 0.4 vs. 1.5; p= 0.02). The surgical-pathological
characteristics of Groups 1 and 2 are presented in Table 3.
Smaller and bilateral tumors, extensive tumoral necrosis
and a surgical finding of extraovarian disease were
associated with a higher probability of secondary ovarian
involvement. High-grade invasive adenocarcinomas with
multinodular patterns of ovarian parenchyma invasion had
a higher probability of being metastatic. The comparative
immunohistochemical study between primary and second-
ary tumors is shown in Table 3. Secondary tumors were
mainly associated with the expression of CK20, CDX-2 and
MUC2 and were negatively associated with a high LVD and
the expression of CK7, CA125 and MUC5AC.
We constructed a logistic regression model including the
patients’ age, tumor size and laterality as predictors of a
secondary tumor. The age of the patient was excluded from
the model. Next, we tested a model with tumor size,
laterality and all the immunohistochemical markers (CK7,
CK20, CDX-2, CA125, CA19.9, MUC2 and MUC5AC). The
variables that remained in the model were tumor size,
laterality, CK7 and MUC2. Finally, we tested the LVD with
these variables in a new model; however, LVD was
Figure 1 - Patterns of invasion in two mucinous adenocarcino-
mas: infiltrative/destructive (A) and confluent with nodular
configuration (B).
Figure 2 - Mucinous carcinomas with intestinal (A), Mullerian (B)
and gastric (C) phenotypes. Focal cytokeratin 7 expression in a
metastatic mucinous carcinoma is shown.
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excluded. The final model identified a tumor size of 10.0 cm
or less (OR 9.4; 95% CI 1.2-69.2), bilaterality (OR 51.5; 95% CI
7.1-370.2) and CK7 negativity (OR 64.8; 95% CI 9.4-447) as
predictors of a secondary deposit. The probability of a
secondary tumor in this model is reduced if MUC2 is
negative (OR 0.1; 95% CI 0.01-0.6). This model allows 90.0%
of all cases to be classified correctly, including 92.2% of
primary tumors and 86.2% of metastases.
& DISCUSSION
Ovarian metastases commonly present as the first sign of
many adenocarcinomas, including (but not limited to)
gastrointestinal adenocarcinomas, with the primary tumor
remaining undiagnosed (13). When compounded by the fact
that some metastatic carcinomas can stimulate primary
tumors, this presentation can lead even experienced
pathologists to incorrectly diagnose a secondary deposit as
a primary neoplasm, causing delays and the implementa-
tion of incorrect therapeutic approaches, with serious
consequences for the patient. In such situations, the use of
morphological criteria can often be helpful; however, none
of these criteria are pathognomonic of metastasis (4,6,13,14).
The main characteristics indicating that a deposit is
secondary are a small tumor size; bilaterality; multiple
nodules on the cut surface; a microscopic pattern of stromal
invasion with a nodular, heterogeneous and infiltrative/
destructive phenotype; surface implants; lymphatic or blood
vessel invasion, especially if conspicuous; and the presence
of signet-ring cells and neoplastic cells floating in mucin
pools (14,15). The pattern of ovarian parenchyma involve-
ment can suggest a secondary neoplasm. In our cases, we
observed that all secondary tumors had a multinodular
pattern of invasion. In a retrospective study of 104 cases
comparing expansive versus infiltrative invasion, the
authors found a worse prognosis and a higher probability
of lymph node metastasis among individuals with the
infiltrative pattern (16). A simple algorithm based on tumor
size and laterality has been previously determined and can
correctly classify 84-90% of the cases (6,15). In addition,
immunohistochemistry may help to identify the profile
determined by coordinated CK7 and CK20 expression. For
example, a CK7-/CK20+ immunoprofile suggests a color-
ectal origin, whereas a CK7+/CK20- profile favors the ovary
as the primary site. However, this ancillary technique has
limitations in this setting because primary mucinous
ovarian tumors may express CK20 focally or, at times,
diffusely (17). Similarly, large bowel adenocarcinomas can
show focal or multifocal staining for CK7, which happens
more frequently in poorly differentiated tumors and in
those localized in the right colon and rectum (18).
Additionally, the CK7+/CK20- immunophenotype is also
observed in adenocarcinomas originating in the pancreas,
breast, stomach, lung, bile ducts and female genital tract
(19). Due to this overlap, it is not advisable to use
immunohistochemistry alone when investigating whether a
mucinous ovary tumor is primary or secondary; rather, this
approach should always be utilized in conjunction with
clinical and morphologic data. In the last few years, new
immunohistochemical markers have been used in combina-
tion with the cytokeratins (CK7 and CK20) to increase the
accuracy of the test. Immunohistochemical markers, such as
Cdx-2, b-catenin, p504, Dpc4, MUC1, MUC2, MUC5AC and
Hep Par, can be useful. However, despite all the available
approaches, there will be cases inwhich doubt will remain. In
this study, we included the most common predictors of
metastatic nature: surgical findings (such as tumor size,
laterality and extraovarian spread) and immunohistochem-
ical markers. Although our study was limited by the use of
TMA for immunohistochemical reactions, our results agreed
with the published data. Interestingly, when multivariate
analysis was performed only on tumors smaller than 10.0 cm,
bilaterality and negative CK7 remained as predictors of
metastasis. Our model accurately predicted 86.2% of metas-
tasis cases; thus, a correct diagnosis could not be obtained for
least 15% of cases.
Therefore, the search for a new tool that may help to
accurately determine whether a mucinous tumor is primary
or metastatic continues.
The lymphatic vasculature is one important route of
neoplastic dissemination for most carcinomas. Additionally,
conspicuous lymphovascular invasion is one of the char-
acteristics indicative of metastases of ovarian tumors (14,15).
On the other hand, the stromal component, which includes
Table 2 - Reagents and methods used for immunohistochemical analyses.
Antigen Clone/source Dilution Epitope retrieval method
CK7 OV-TL 12/30 MOUSE IgG1/DAKO 1/1000 PT LINK 20 minutes, low pH
CK20 KS20.8 Ks20.8 MOUSE IgG2a/ZETA 1/800 PT LINK 20 minutes, low pH
CA125 OC 125 MOUSE IgG1/ZYMED 1/800 PT LINK 20 minutes, low pH
CDX-2 DAK-CDX-2 MOUSE IgG1/DAKO 1/800 PT LINK 20 minutes, high pH
CA19.9 SPM110 MOUSE IgG1/NEOMARKERS 1/1600 PT LINK 20 minutes, low pH
MUC2 Ccp 58 MOUSE IgG1/NOVOCASTRA 1/100 PT LINK 20 minutes, high pH
MUC5AC CLH2 MOUSE IgG1/NOVOCASTRA 1/200 PT LINK 20 minutes, high pH
Podoplanin D2-40 MOUSE IgG1/DAKO 1/200 PT LINK 20 minutes, low pH
Figure 3 -Mucinous ovarian tumor showing ten lymphatic vessels
identified by podoplanin staining using the D2-40 antibody
(original magnification 200X).
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the lymphovascular spaces, is an important component of
epithelial ovarian tumors (20,21). Therefore, we decided to
investigate the potential role of the intratumoral LVD in the
characterization of a mucinous tumor as primary or
secondary. Published studies examining LVD in patients
with ovarian tumors were generally designed to evaluate
the behavior of primary carcinomas but not to help identify
secondary tumors. For example, intratumoral and peritu-
moral LVD have been studied in borderline ovarian serous
tumors in an attempt to determine their role in nodal
metastasis (22). No association between LVD and nodal
metastasis could be demonstrated, perhaps because the
nodal tumor deposits observed in borderline tumors do not
occur via tumoral lymphatics (22). Lymphangiogenesis was
also investigated by Sundar et al. in 108 ovarian tumors,
including 12 mucinous type tumors. In that study, lympha-
tic vessel density was statistically significant in a multi-
variate analysis of overall survival and progression-free
survival. However, lymphatic counts did not impact the
survival curves. The authors suggested that lymphatic
spread might act in conjunction with other biological factors
to cause metastasis (23).
In our previous experience with cancers of the vulva,
cervix and endometrium, we found an inverse correlation
between intratumoral LVD and lymph node metastasis and
prognosis (9-11). To explain our previous results, we
hypothesized that the intratumoral lymphatic vessels were
non-functional and therefore had the potential to disturb
local drainage, including the transport of neoplastic cells
outside the tumor. Another hypothesis to be considered is
that the intratumoral lymphatics are important in the early
steps of neoplastic progression, just prior to the transport of
cells outside of the tumor. Once the dissemination has
begun, intratumoral lymphangiogenesis is no longer neces-
sary. In this study, we aimed to determine a possible role for
LVD in the definition of primary or secondary origin.
Although primary tumors showed higher LVDs, this
difference did not offer any advantage over the classical
features (tumor size, laterality and CK7 expression) with
respect to the diagnosis. In routine surgical pathology, 90%
Table 3 - Surgical-pathological variables and immunohistochemical characteristics of 124 cases of mucinous ovarian
tumors.
Feature Categories Primary (n= 63) Metastatic (n = 61) OR (95% CI) p
Tumor size .10 cm 48 (76.19%) 21 (34.42%) 5.9 (1.9-18.8) 0.002
#10 cm 5 (7.93%) 13 (21.31%)
unknown 10 (15.87%) 27 (44.26%)
Bilaterality yes 6 (9.52%) 20 (32.78%) 5 (1.8-13.6) 0.001
no 57 (90.47%) 38 (62.29%)
unknown 0 (0%) 3 (4.91%)
Patterns of stromal invasion * infiltrative 15 31 1.5 (0.6-3.7) 0.32




Histologic grade* 1 16 15
2 16 24 1.6 (0.6-4.1) 0.33
3 1 16 13.1 (1.6-104.4) 0.01
Extra-ovarian disease yes 8 (12.69%) 36 (59.01%) 9.9 (4-24.3) ,0.0001
no 55 (87.30%) 25 (40.98%)
Necrosis ,50% 32 (50.79%) 43 (70.49%) 8.9 (1.1-72.2) 0.04
.50% 1 (1.58%) 12 (19.67%)
unknown 30 (47.61%) 6 (9.83%)
CK7 positive 58 (92.06%) 18 (29.50%) 0.04 (0.01-0.1) ,0.0001
negative 5 (7.93%) 42 (68.85%)
unknown 0 (0%) 1 (1.63%)
CK20 positive 37 (58.73%) 52 (85.24%) 4.6 (1.8-11.2) 0.0009
negative 26 (41.26%) 8 (13.11%)
unknown 0 (0%) 1 (1.63%)
CDX-2 positive 45 (71.42%) 57 (93.44%) 7.6 (2.1-27.4) 0.002
negative 18 (28.57%) 3 (4.91%)
unknown 0 (0%) 1 (1.63%)
CA125 positive 38 (60.31%) 7 (11.47%) 0.08 (0.03-0.2) ,0.0001
negative 24 (38.09%) 53 (86.88%)
unknown 1(1.58%) 1 (1.63%)
CA19.9 positive 49 (77.77%) 37 (60.65%) 0.4 (0.2-0.9) 0.04
negative 13 (20.63%) 23 (37.70%)
unknown 1(1.58%) 1 (1.63%)
MUC2 positive 34 (53.96%) 56 (91.80) 11.5 (3.7-35.7) ,0.0001
negative 28 (44.44%) 4 (6.55%)
unknown 1(1.58%) 1 (1.63%)
MUC5AC positive 50 (79.36%) 25 (40.98%) 0.2 (0.08-0.4) ,0.0001
negative 13 (20.63%) 35 (57.37%)
unknown 0 (0%) 1 (1.63%)
LVD high (.0.8) 36 (57.14%) 23 (37.70%) 0.4 (0.2-0.9) 0.02
low (#0.8) 26 (41.26%) 38 (62.29%)
unknown 1(1.58%) 0 (0%)
*Evaluated only among cases of non-borderline morphology.
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of the cases can be reliably categorized using these
predictors (size # 10.0 cm, bilaterality and lack of CK7
expression). Our deceptive results with the LVD did not
exclude the possibility of other differences between the
stroma of primary and secondary tumors, which may or
may not involve the lymphatic vasculature. On the other
hand, recent studies have advocated a change in the
paradigm with regard to what concerns an ‘‘extraovarian
origin’’ of epithelial ovarian cancer (either from tubal
fimbria or from endometriosis) (24,25). Because all epithelial
ovarian tumors might be secondary, this could explain why
no great differences were detected in LVD between our two
study groups.
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